MX9702181A - Preparacion de combinacion, que contiene ciclosporina a o bien fk506 o bien rapamicina y un derivado de xantina. - Google Patents

Preparacion de combinacion, que contiene ciclosporina a o bien fk506 o bien rapamicina y un derivado de xantina.

Info

Publication number
MX9702181A
MX9702181A MX9702181A MX9702181A MX9702181A MX 9702181 A MX9702181 A MX 9702181A MX 9702181 A MX9702181 A MX 9702181A MX 9702181 A MX9702181 A MX 9702181A MX 9702181 A MX9702181 A MX 9702181A
Authority
MX
Mexico
Prior art keywords
xanthine derivative
rapamycin
combination preparation
containing cyclosporin
xanthine
Prior art date
Application number
MX9702181A
Other languages
English (en)
Other versions
MXPA97002181A (es
Inventor
Martin Schonharting
Ulrich Gebert
Mark Waer
Original Assignee
Hoechst Ag
Univ Leuven Kath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag, Univ Leuven Kath filed Critical Hoechst Ag
Publication of MXPA97002181A publication Critical patent/MXPA97002181A/es
Publication of MX9702181A publication Critical patent/MX9702181A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Preparaciones de combinacion que contienen ciclosporina A y un derivado de kantina o bien FX506 y un derivado de kantina o rapamicina y un derivado de kantina son adecuados para su uso en transplante de organos como por ejemplo lupus eritematoso sistématico, artritis reumatoide, psoriasis, pénfigo, dermatitis atopica, miositis, esclerosis multiple, síndrome nefrotico (especialmente glomerulonefritis), colitis ulcerativa o bien diabetes juvenil.
MX9702181A 1994-08-25 1995-08-07 Preparacion de combinacion, que contiene ciclosporina a o bien fk506 o bien rapamicina y un derivado de xantina. MX9702181A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4430127A DE4430127A1 (de) 1994-08-25 1994-08-25 Kombinationspräparat, enthaltend Cyclosporin A oder FK506 und ein Xanthinderivat
DEP4430127.9 1994-08-25
PCT/EP1995/003126 WO1996005854A2 (en) 1994-08-25 1995-08-07 Combination preparation, containing cyclosporin a or fk506 or rapamycin and a xanthine derivative

Publications (2)

Publication Number Publication Date
MXPA97002181A MXPA97002181A (es) 1997-06-01
MX9702181A true MX9702181A (es) 1997-06-28

Family

ID=6526514

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9702181A MX9702181A (es) 1994-08-25 1995-08-07 Preparacion de combinacion, que contiene ciclosporina a o bien fk506 o bien rapamicina y un derivado de xantina.

Country Status (9)

Country Link
US (2) US6046328A (es)
EP (1) EP0797448B1 (es)
CN (1) CN1096859C (es)
AT (1) ATE233095T1 (es)
AU (1) AU714129B2 (es)
CA (1) CA2199949A1 (es)
DE (2) DE4430127A1 (es)
MX (1) MX9702181A (es)
WO (1) WO1996005854A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2408408C (en) * 2000-05-12 2013-07-09 Genzyme Corporation Modulators of tnf- alpha signaling
US20040137066A1 (en) * 2001-11-26 2004-07-15 Swaminathan Jayaraman Rationally designed therapeutic intravascular implant coating
US6641611B2 (en) 2001-11-26 2003-11-04 Swaminathan Jayaraman Therapeutic coating for an intravascular implant
JP4914008B2 (ja) * 2002-11-21 2012-04-11 ジェンザイム・コーポレーション 免疫寛容を誘導するためのジアミド誘導体と免疫抑制剤との組み合わせ
PT1567138E (pt) * 2002-11-21 2011-04-11 Genzyme Corp Utilização de derivados de diamida para inibição de rejeição crónica de transplante
US20070105878A1 (en) * 2005-10-03 2007-05-10 Andrew Reaume Purine formulations and methods for managing disorders
EP1787645A1 (en) * 2005-11-18 2007-05-23 Institut Curie New method for treating cancer based on the modulation of the calcineurin and/or the calcineurin/NFAT pathway
CN102026645B (zh) 2006-09-15 2016-01-27 渥太华医院研究机构 溶瘤弹状病毒
PT2079456E (pt) * 2007-04-04 2013-03-13 Sigmoid Pharma Ltd Composições farmacêuticas de ciclosporina
JP5567503B2 (ja) 2008-02-29 2014-08-06 コンサート ファーマシューティカルズ インコーポレイテッド 置換キサンチン誘導体
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
US8263601B2 (en) 2009-02-27 2012-09-11 Concert Pharmaceuticals, Inc. Deuterium substituted xanthine derivatives
CN101897964B (zh) * 2009-04-27 2013-04-10 中国农业大学 一种预防自身免疫疾病的药物
WO2011028820A1 (en) 2009-09-02 2011-03-10 Concert Pharmaceuticals, Inc. Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds
WO2012031072A1 (en) 2010-09-01 2012-03-08 Concert Pharmaceuticals, Inc. Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation
US9074233B2 (en) 2010-09-01 2015-07-07 Concert Pharmaceuticals, Inc. Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation
CN104364255A (zh) 2012-04-13 2015-02-18 康塞特医药品有限公司 取代的黄嘌呤衍生物
EP2705856A1 (en) 2012-09-07 2014-03-12 Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. Compounds for the treatment of neurodegenerative disorders
WO2015073691A1 (en) * 2013-11-14 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating cancer by activation of bmp signaling
CN116264834A (zh) * 2020-08-25 2023-06-16 广东众生睿创生物科技有限公司 羟基嘌呤类化合物用于治疗皮肤疾病的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9084991A (en) * 1990-11-01 1992-05-26 Board Of Regents, The University Of Texas System Antifungal activity of and prevention of drug induced nephrotoxicity by methylxanthine analogues
EP0490181A1 (en) * 1990-11-30 1992-06-17 Hoechst-Roussel Pharmaceuticals Incorporated Use of xanthines for preparation of a medicament having immunosuppressing activity
EP0493682A3 (en) * 1990-11-30 1992-11-19 Hoechst-Roussel Pharmaceuticals Incorporated Use of xanthines for the preparation of a medicament effective for inhibiting the effects of allograft reaction in humans
IL99368A (en) * 1991-09-02 1996-01-19 Teva Pharma Preparations for the treatment of psoriasis and atopic dermatitis, which contain the result of xanthine
ATE230990T1 (de) * 1992-03-04 2003-02-15 Cell Therapeutics Inc Enantiomere hydroxylierte xanthinverbindungen

Also Published As

Publication number Publication date
AU3342895A (en) 1996-03-14
DE4430127A1 (de) 1996-03-14
US6046328A (en) 2000-04-04
EP0797448A2 (en) 1997-10-01
CN1162919A (zh) 1997-10-22
DE69529769D1 (de) 2003-04-03
ATE233095T1 (de) 2003-03-15
AU714129B2 (en) 1999-12-16
CA2199949A1 (en) 1996-02-29
WO1996005854A2 (en) 1996-02-29
CN1096859C (zh) 2002-12-25
EP0797448B1 (en) 2003-02-26
WO1996005854A3 (en) 1996-04-11
US6432968B1 (en) 2002-08-13

Similar Documents

Publication Publication Date Title
MX9702181A (es) Preparacion de combinacion, que contiene ciclosporina a o bien fk506 o bien rapamicina y un derivado de xantina.
MY134806A (en) Cyclosporins
HU9600298D0 (en) C 22-ring stabilized rapamycin derivatives
AU4098797A (en) Imidazo(4,5-c)pyridin-4-amines
AU7211691A (en) Novel vehicle gases and their use in medical preparations
WO1997003654A3 (en) Pharmaceutical compositions
AU6019594A (en) Text input transliteration system
EP1707641A3 (en) Evolution of whole cells and organisms by recursive sequence recombination
MY109822A (en) (s)-(+)-hydroxychloroquine
AU7107794A (en) Cd28 pathway immunosuppression
WO2001027118A3 (de) Bicyclische imidazo-5-yl-aminderivate
DE3886986D1 (de) Glykoprotein, Verfahren zu dessen Herstellung und dieses als aktiven Bestandteil enthaltendes immunsuppressives Agens.
AU1319895A (en) Cyclodextrin derivatives for solubilising hydrophobic chemical compounds such as drugs, and methods for preparing same
GB9927624D0 (en) Remotely controlled submersible vehicle for subsea tooling
AU2374100A (en) Products comprising trihydroxystilbenes and derivatives thereof and methods for their manufacture and use
ATE205496T1 (de) Desosamino-derivate von makroliden als immunosuppressive und antifungale mittel
WO1994026263A3 (en) Use of a transition metal complex for the treatment of septic shock
AU4823993A (en) Polypeptides involved in streptogramin biosynthesis, nucleotide sequences coding for said polypeptides and use thereof
AU7427194A (en) Control mechanism for the seat carriers of chairs, especially swivel chairs
AU8131694A (en) Treatment for rheumatoid arthritis
IL110585A0 (en) Tripeptides, their preparation and pharmaceutical compositions containing them
EP0828258A3 (en) Dielectric fluids
石祥恩 et al. Factors Influencing the Postoperative Survival Time of Patients with Brain Glioblastoma
王国明 THE" ORGAN VERBS
Chen et al. FK-520 microbial transformation product.